1. What Is NAD+
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every living cell. It is a dinucleotide — two nucleotides joined by a pyrophosphate bridge — with one nucleotide carrying a nicotinamide group and the other carrying an adenine base. NAD+ participates in hundreds of enzymatic reactions across cellular metabolism, serving as both an electron carrier in redox reactions and a substrate consumed by signaling enzymes.
Unlike most compounds in the research peptide market, NAD+ is not a peptide. It is a small molecule coenzyme with a molecular weight of 663.43 Da (CAS 53-84-9). Interest in exogenous NAD+ supplementation — via oral precursors such as nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR), or via intravenous infusion — has grown substantially due to research linking declining NAD+ levels to aging and age-related disease.
NAD+ exists in two forms: the oxidized form (NAD+) and the reduced form (NADH). The oxidized form is the version most commonly sold as a supplement or research compound. The body synthesizes NAD+ through three pathways: the salvage pathway (which recycles nicotinamide and produces the majority of cellular NAD+), the Preiss-Handler pathway (from dietary niacin), and the de novo pathway (from the amino acid tryptophan).
2. Mechanism of Action
NAD+ functions through two distinct roles in the cell: as a redox cofactor shuttling electrons in metabolic reactions, and as a consumed substrate for signaling enzymes. Its role in aging research centers on the latter.
Sirtuins (SIRT1–SIRT7)
Sirtuins are a family of NAD+-dependent deacetylases and ADP-ribosyltransferases involved in DNA repair, gene expression, mitochondrial function, and stress response. SIRT1 and SIRT3 have received the most attention in aging research. Sirtuins consume NAD+ as a co-substrate — they do not merely bind it — meaning their activity is directly limited by NAD+ availability.
PARPs (Poly-ADP-Ribose Polymerases)
PARPs are DNA repair enzymes that consume large quantities of NAD+ when activated by DNA damage. PARP1 in particular is a major NAD+ consumer. Chronic DNA damage — which increases with age — leads to sustained PARP activation and significant NAD+ depletion, which may in turn impair sirtuin activity.
CD38
CD38 is an ectoenzyme expressed on immune cells that degrades NAD+. CD38 expression increases with age and inflammation, and it has been identified as a major driver of age-related NAD+ decline in animal models. CD38 activity can deplete NAD+ at a rate that outpaces synthesis.
Metabolic Redox Reactions
In its electron-carrier role, NAD+ accepts electrons during glycolysis and the citric acid cycle, becoming NADH, which then donates those electrons to the mitochondrial electron transport chain for ATP production. The NAD+/NADH ratio is a fundamental regulator of cellular energy metabolism.
3. Clinical Evidence
The clinical evidence for NAD+ supplementation in humans is still developing. Most human trial data comes from oral NAD+ precursors (NMN and NR) rather than direct NAD+ administration. Here is what the data shows as of October 2026:
Regulatory Status
- NAD+ is not FDA-approved as a drug for any indication. Oral NAD+ supplements may be sold under the dietary supplement framework.
- No FDA-approved IV NAD+ products exist. IV NAD+ is available through compounding pharmacies (503A/503B facilities), which operate under different quality oversight than traditional pharmaceutical manufacturing.
- FDA enforcement actions have occurred. In 2024, the FDA warned that some compounders were using oral-grade NAD+ to prepare sterile IV formulations. In 2025, the FDA issued a Class I recall of compounded NAD+ for injection due to elevated endotoxin levels.
- WADA considerations. NAD+ is not specifically named on the 2026 WADA Prohibited List, but its S0 category covers non-approved pharmacological substances. WADA also limits IV infusions to 100 mL within 12 hours outside of hospital settings — many NAD+ IV protocols exceed this threshold.
4. What to Look for in a COA
When evaluating a Certificate of Analysis for an NAD+ product, confirm the following:
Identity confirmation via mass spectrometry showing molecular weight near 663.43 Da
HPLC purity of 98% or higher — research-grade NAD+ from reputable sources typically meets this standard
Endotoxin testing (critical for any injectable or IV product) — the FDA recall cited endotoxin levels exceeding safe limits
Sterility testing for injectable preparations, performed by an independent third-party lab
Heavy metals screening (arsenic, lead, mercury, cadmium) within acceptable limits
A batch or lot number matching the product you received
A verifiable lab reference number from an independent, named testing laboratory
Test date — NAD+ degrades over time, especially in solution; a COA from months or years ago may not reflect current product quality
Red flags on an NAD+ COA: missing identity confirmation (HPLC alone does not confirm the compound is NAD+), purity below 95%, absence of endotoxin results on injectable products, no named testing laboratory, or a test date that significantly predates the product's manufacture date.
For a full walkthrough of evaluating a COA, see our guide to reading a peptide COA.
5. Testing Considerations
NAD+ presents specific analytical and quality challenges that distinguish it from peptide compounds:
Analytical Methods
NAD+ identity and purity are typically assessed using HPLC (High-Performance Liquid Chromatography) for purity determination and LC-MS (Liquid Chromatography–Mass Spectrometry) for identity confirmation. UV-Vis spectrophotometry can also confirm NAD+ by its characteristic absorption peak at 260 nm (and at 340 nm for the reduced NADH form). Mass spectrometry should confirm the molecular ion at m/z 664.4 [M+H]+ or 662.4 [M-H]−.
Stability and Storage
NAD+ powder is stable when stored at -20°C, with a reported shelf life of approximately 3 years under these conditions. In solution, stability drops significantly — NAD+ solutions should be stored at -80°C and used within one year, or at -20°C and used within one month. NAD+ is sensitive to heat, moisture, and prolonged light exposure. Once reconstituted, degradation accelerates, and the solution should be kept cold and protected from light. Repeated freeze-thaw cycles should be avoided.
Market Quality Concerns
Independent testing has revealed significant quality issues in the NAD+ supplement market. A 2026 SuppCo analysis of 10 NAD+ supplement products found that only 4 passed content testing — several contained less than 5% of their labeled NAD+ amount, and one had no detectable NAD+ at all. The FDA has separately cited compounded NAD+ preparations with impurity levels exceeding 20% in certain samples. These findings underscore the importance of independent, third-party verification.
Injectable-Specific Risks
IV NAD+ preparations carry additional risks beyond purity. Sterility, endotoxin levels (measured via the LAL test), and particulate matter must all be verified. FDA adverse event reports have described severe reactions — including chills, violent shaking, and vomiting — consistent with endotoxin contamination. Research-grade NAD+ is not manufactured under pharmaceutical GMP standards and is not suitable for injection without further processing and testing.
Substitution and Adulteration
Because NAD+ and its precursors (NMN, NR, niacin, niacinamide) are related but distinct compounds, substitution is a documented concern. An HPLC test alone may not distinguish NAD+ from its precursors or degradation products without proper reference standards. Mass spectrometric confirmation is essential to verify that the product contains NAD+ specifically, rather than a cheaper precursor or a degradation product such as ADPR (adenosine diphosphate ribose).
Summary
NAD+ is an endogenous coenzyme central to cellular energy metabolism and signaling. While declining NAD+ levels are associated with aging in research models, clinical evidence for NAD+ supplementation in humans remains limited and mixed — particularly for IV administration, which lacks controlled trial data entirely. Independent testing has exposed substantial quality failures in the NAD+ market, with multiple products containing far less NAD+ than labeled.
When evaluating an NAD+ product, prioritize third-party lab testing showing HPLC purity at or above 98%, mass spectrometric identity confirmation at 663.43 Da, and — for any injectable product — verified endotoxin and sterility testing from an independent laboratory.